\-\ Texto\\:\\ \ \(0\)\
\-\ this\\ woman\\ is\\ status\\ post\\ craniotomy\\ for\\ breast\\ cancer\\ metastatic\\ to\\ brain\\ \\-\\ a\\ piece\\ of\\ history\\ that\\ was\\ witheld\\.\\ \\ prognosis\\ is\\ generally\\ improved\\ if\\ cerebral\\ metastatic\\ deposits\\ are\\ treated\\ or\\ removed\\.\\ \\ she\\ has\\ also\\ received\\ chemotherapy\\.\\ the\\ new\\ presence\\ of\\ drop\\ metastases\\ in\\ the\\ spine\\ has\\ a\\ poor\\ prognosis\\.\\ \\ these\\ spinal\\ lesions\\ may\\ have\\ resulted\\ from\\ direct\\ hematogenous\\ spread\\ to\\ nerve\\ roots\\ \\-\\ or\\,\\ they\\ may\\ be\\ \\"drop\\ mets\\"\\ from\\ the\\ previous\\ brain\\ lesions\\.\ \(0\)\
\-\ diffuse\\ nodular\\ areas\\ of\\ enhancement\\ along\\ the\\ surface\\ of\\ the\\ spinal\\ cord\\ and\\ about\\ the\\ nerve\\ roots\\ of\\ the\\ cauda\\ equina\\.\ \(0\)\
\-\ droplet\\ metastases\ \(0\)\
\-\ drop\\ metastases\\:\ \(0\)\
\-\ \\Â\\»\\ primitive\\ neuroectodermal\\ tumor\\ \\(pnet\\)\ \(0\)\
\-\ \\Â\\»\\ medulloblastoma\ \(0\)\
\-\ \\Â\\»\\ anaplastic\\ or\\ malignant\\ astrocytoma\ \(0\)\
\-\ \\Â\\»\\ ependymoma\ \(0\)\
\-\ \\Â\\»\\ germinoma\ \(0\)\
\-\ \\Â\\»\\ pineoblastoma\ \(0\)\
\-\ \\Â\\»\\ choroid\\ plexus\\ carcinoma\ \(0\)\
\-\ hematogenous\\ spread\\ from\\ primary\\ lung\\ or\\ breast\\ cancer\\,\\ melanoma\\,\\ non\\-hodgkin\\ lymphoma\ \(0\)\
\-\ less\\ likley\\.\\.\\.\ \(0\)\
\-\ \\Â\\»\\ arachnoiditis\ \(0\)\
\-\ \\Â\\»\\ granulomatous\\ disease\ \(0\)\
\-\ \\Â\\»\\ neurofibromatosis\ \(0\)\
\-\ \\â\\€\\¢\\ nf1\\ \\-\\ neurofibromas\ \(0\)\
\-\ \\â\\€\\¢\\ nf2\\ \\-\\ schwannoma\ \(0\)\
\-\ \\Â\\»\\ epidermoid\\ dissemination\ \(0\)\
\-\ this\\ 43\\-year\\-old\\ woman\\ has\\ a\\ history\\ of\\ breast\\ cancer\\.\ \(0\)\
\-\ intradural\\ extramedullary\\ spinal\\ metastases\\ occur\\ hematogenously\\ or\\ via\\ csf\\ seeding\\.\\ hematogenous\\ spread\\ is\\ most\\ common\\ and\\ usually\\ occurs\\ with\\ lung\\ and\\ breast\\ carcinomas\\,\\ and\\ melanoma\\.\\ cns\\ tumors\\ with\\ access\\ to\\ the\\ ventricular\\ system\\ such\\ as\\ medulloblastoma\\,\\ ependymoma\\,\\ and\\ choroid\\ plexus\\ carcinoma\\ or\\ aggressive\\ tumors\\ such\\ as\\ glioblastoma\\ multiforme\\ are\\ usually\\ responsible\\ for\\ csf\\ seeding\\.\\ cortical\\ tumors\\ that\\ breach\\ the\\ pial\\ surface\\ \\(like\\ metastases\\ and\\ oligodendroglioma\\)\\ may\\ also\\ cause\\ csf\\ spread\\.\ \(0\)\
\-\ drop\\ metastases\\ are\\ likely\\ to\\ be\\ found\\ in\\ the\\ pediatric\\ population\\,\\ where\\ they\\ are\\ related\\ to\\ medulloblastoma\\,\\ ependymoma\\,\\ choroid\\ plexus\\ tumors\\,\\ or\\ pineal\\ germ\\ cell\\ neoplasms\\.\\ these\\ lesions\\ typically\\ occur\\ in\\ the\\ dorsal\\ lower\\-thoracic\\ to\\ lumbar\\ spine\\,\\ with\\ the\\ nerve\\ roots\\ and\\ the\\ cauda\\ equina\\ as\\ common\\ sites\\ of\\ spread\\ \\-\\ probably\\ due\\ to\\ upright\\ posture\\ and\\ gravity\\.\ \(0\)\
\-\ mr\\ imaging\\ is\\ the\\ best\\ modality\\ to\\ use\\ to\\ evaluate\\ the\\ contents\\ of\\ the\\ spinal\\ canal\\ and\\ detect\\ drop\\ metastases\\.\\ subarachnoid\\ tumor\\ implants\\ are\\ typically\\ hyperintense\\ to\\ csf\\ on\\ t1\\ and\\ hypointense\\ on\\ t2\\.\\ \ \(0\)\
\-\ post\\-gadolinium\\ images\\ demonstrate\\ diffuse\\ linear\\ and\\ nodular\\ areas\\ of\\ enhancement\\ along\\ the\\ nerve\\ roots\\ and\\ the\\ peripheral\\ surface\\ of\\ the\\ cord\\.\\ \ \(0\)\
\-\ processes\\ such\\ as\\ arachnoiditis\\,\\ neurofibromatosis\\ and\\ granulomatous\\ disease\\ may\\ demonstrate\\ a\\ similar\\ nodular\\ enhancement\\ and\\ clinical\\ history\\ is\\ helpful\\ in\\ narrowing\\ the\\ differential\\.\\ arachnoiditis\\ may\\ show\\ clumping\\ of\\ nerve\\ roots\\.\ \(0\)\
\-\ depending\\ on\\ the\\ number\\ of\\ lesions\\,\\ position\\,\\ and\\ extent\\ of\\ lesions\\,\\ the\\ management\\ of\\ drop\\ metastases\\ may\\ consist\\ of\\ steroids\\,\\ local\\ radiation\\ therapy\\,\\ or\\ surgery\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ drop\\:\\ 0\\.2861229436553063\ \(0\)\
\-\ metastases\\:\\ 0\\.2835466387514663\ \(0\)\
\-\ roots\\:\\ 0\\.23266074926359986\ \(0\)\
\-\ spread\\:\\ 0\\.1969170765868126\ \(0\)\
\-\ the\\:\\ 0\\.19245486553230096\ \(0\)\
\-\ arachnoiditis\\:\\ 0\\.18500539060361298\ \(0\)\
\-\ nerve\\:\\ 0\\.1563811486212231\ \(0\)\
\-\ hematogenous\\:\\ 0\\.14948770279023987\ \(0\)\
\-\ csf\\:\\ 0\\.13856808978958501\ \(0\)\
\-\ medulloblastoma\\:\\ 0\\.13658476998641578\ \(0\)\
\-\ and\\:\\ 0\\.13588933704155925\ \(0\)\
\-\ may\\:\\ 0\\.1323742577359137\ \(0\)\
\-\ tumors\\:\\ 0\\.12897237934335504\ \(0\)\
\-\ of\\:\\ 0\\.12869352709062387\ \(0\)\
\-\ breast\\:\\ 0\\.12734541978883251\ \(0\)\
\-\ lesions\\:\\ 0\\.12589307470157202\ \(0\)\
\-\ spinal\\:\\ 0\\.1245211856498471\ \(0\)\
\-\ choroid\\:\\ 0\\.12334815884772625\ \(0\)\
\-\ or\\:\\ 0\\.12201314696276644\ \(0\)\
\-\ plexus\\:\\ 0\\.11857723538677278\ \(0\)\
\-\ seeding\\:\\ 0\\.1126824367482302\ \(0\)\
\-\ ependymoma\\:\\ 0\\.11109800086511781\ \(0\)\
\-\ surface\\:\\ 0\\.10973687827418195\ \(0\)\
\-\ to\\:\\ 0\\.10960264577235644\ \(0\)\
\-\ nodular\\:\\ 0\\.10473923672615933\ \(0\)\
\-\ equina\\:\\ 0\\.10268213793620382\ \(0\)\
\-\ cauda\\:\\ 0\\.10202794642738508\ \(0\)\
\-\ cancer\\:\\ 0\\.08760442245391174\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.08695144308768575\ \(0\)\
\-\ such\\:\\ 0\\.0846030742624262\ \(0\)\
\-\ are\\:\\ 0\\.08317909229881201\ \(0\)\
\-\ melanoma\\:\\ 0\\.08188274585215181\ \(0\)\
\-\ granulomatous\\:\\ 0\\.07794317752352806\ \(0\)\
\-\ prognosis\\:\\ 0\\.07716142361996316\ \(0\)\
\-\ enhancement\\:\\ 0\\.07570304475976368\ \(0\)\
\-\ as\\:\\ 0\\.07045058977852507\ \(0\)\
\-\ likley\\:\\ 0\\.07011194734595569\ \(0\)\
\-\ droplet\\:\\ 0\\.06699570869496023\ \(0\)\
\-\ clumping\\:\\ 0\\.06699570869496023\ \(0\)\
\-\ cord\\:\\ 0\\.06499577822931578\ \(0\)\
\-\ breach\\:\\ 0\\.06478470218553312\ \(0\)\
\-\ occur\\:\\ 0\\.06448618967167752\ \(0\)\
\-\ hematogenously\\:\\ 0\\.06306971230004037\ \(0\)\
\-\ they\\:\\ 0\\.06265099299326277\ \(0\)\
\-\ typically\\:\\ 0\\.06155428877576398\ \(0\)\
\-\ witheld\\:\\ 0\\.06048372458425842\ \(0\)\
\-\ has\\:\\ 0\\.06007642607534402\ \(0\)\
\-\ is\\:\\ 0\\.06003133005014104\ \(0\)\
\-\ areas\\:\\ 0\\.05953054403926787\ \(0\)\
\-\ nf2\\:\\ 0\\.059457457025110565\ \(0\)\
\-\ along\\:\\ 0\\.058744122908181935\ \(0\)\
\-\ posture\\:\\ 0\\.058552224883542205\ \(0\)\
\-\ spine\\:\\ 0\\.057923136610610784\ \(0\)\
\-\ pial\\:\\ 0\\.05774246713961781\ \(0\)\
\-\ pineoblastoma\\:\\ 0\\.057009952158179916\ \(0\)\
\-\ dissemination\\:\\ 0\\.057009952158179916\ \(0\)\
\-\ neurofibromas\\:\\ 0\\.055726042926475684\ \(0\)\
\-\ usually\\:\\ 0\\.055199574802961865\ \(0\)\
\-\ diffuse\\:\\ 0\\.05498797212515037\ \(0\)\
\-\ brain\\:\\ 0\\.054661229418839295\ \(0\)\
\-\ piece\\:\\ 0\\.05462622848862234\ \(0\)\
\-\ gravity\\:\\ 0\\.05462622848862234\ \(0\)\
\-\ neuroectodermal\\:\\ 0\\.053664275866920325\ \(0\)\
\-\ lung\\:\\ 0\\.05333846408076318\ \(0\)\
\-\ nf1\\:\\ 0\\.05322497972311964\ \(0\)\
\-\ germinoma\\:\\ 0\\.05280944121856006\ \(0\)\
\-\ carcinoma\\:\\ 0\\.05244789113756771\ \(0\)\
\-\ from\\:\\ 0\\.0522358395050751\ \(0\)\
\-\ implants\\:\\ 0\\.05168270699775735\ \(0\)\
\-\ history\\:\\ 0\\.05024986161749063\ \(0\)\
\-\ primitive\\:\\ 0\\.05010874107212419\ \(0\)\
\-\ responsible\\:\\ 0\\.05010874107212419\ \(0\)\
\-\ deposits\\:\\ 0\\.04982923426341329\ \(0\)\
\-\ consist\\:\\ 0\\.04982923426341329\ \(0\)\
\-\ common\\:\\ 0\\.04972619402131741\ \(0\)\
\-\ these\\:\\ 0\\.04951446642652409\ \(0\)\
\-\ extramedullary\\:\\ 0\\.049298983328199784\ \(0\)\
\-\ carcinomas\\:\\ 0\\.049046974188086456\ \(0\)\
\-\ access\\:\\ 0\\.049046974188086456\ \(0\)\
\-\ intradural\\:\\ 0\\.048802966704265434\ \(0\)\
\-\ upright\\:\\ 0\\.048802966704265434\ \(0\)\
\-\ pineal\\:\\ 0\\.04833703070649776\ \(0\)\
\-\ anaplastic\\:\\ 0\\.048114244377920536\ \(0\)\
\-\ metastatic\\:\\ 0\\.048089632587336804\ \(0\)\
\-\ post\\:\\ 0\\.047711012944124234\ \(0\)\
\-\ detect\\:\\ 0\\.04728255911505766\ \(0\)\
\-\ pnet\\:\\ 0\\.04708797681877268\ \(0\)\
\-\ craniotomy\\:\\ 0\\.046898199518064364\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.04601382380767935\ \(0\)\
\-\ tumor\\:\\ 0\\.04586319461988498\ \(0\)\
\-\ multiforme\\:\\ 0\\.045686728053269975\ \(0\)\
\-\ woman\\:\\ 0\\.04566549182565321\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0455838602989634\ \(0\)\
\-\ mets\\:\\ 0\\.045071552605630553\ \(0\)\
\-\ resulted\\:\\ 0\\.04464047195184204\ \(0\)\
\-\ contents\\:\\ 0\\.04384470072710897\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.04371972902766389\ \(0\)\
\-\ in\\:\\ 0\\.04362527271074391\ \(0\)\
\-\ modality\\:\\ 0\\.0433565627201378\ \(0\)\
\-\ processes\\:\\ 0\\.043123648223820456\ \(0\)\
\-\ sites\\:\\ 0\\.04278699921749797\ \(0\)\
\-\ probably\\:\\ 0\\.04257048940227452\ \(0\)\
\-\ depending\\:\\ 0\\.04176073165835011\ \(0\)\
\-\ helpful\\:\\ 0\\.041570954357641805\ \(0\)\
\-\ population\\:\\ 0\\.04147779454823234\ \(0\)\
\-\ also\\:\\ 0\\.041243478806798996\ \(0\)\
\-\ cns\\:\\ 0\\.04094137292607591\ \(0\)\
\-\ germ\\:\\ 0\\.04094137292607591\ \(0\)\
\-\ neoplasms\\:\\ 0\\.04085549951678177\ \(0\)\
\-\ dorsal\\:\\ 0\\.04043996101222217\ \(0\)\
\-\ number\\:\\ 0\\.040359482892847416\ \(0\)\
\-\ extent\\:\\ 0\\.04012298453534387\ \(0\)\
\-\ on\\:\\ 0\\.03972256849530685\ \(0\)\
\-\ subarachnoid\\:\\ 0\\.039454250751279056\ \(0\)\
\-\ pediatric\\:\\ 0\\.039243673464466375\ \(0\)\
\-\ improved\\:\\ 0\\.038905046439814975\ \(0\)\
\-\ direct\\:\\ 0\\.038644493007354654\ \(0\)\
\-\ hypointense\\:\\ 0\\.03858071180998158\ \(0\)\
\-\ steroids\\:\\ 0\\.038517455566686405\ \(0\)\
\-\ received\\:\\ 0\\.03814847638342032\ \(0\)\
\-\ epidermoid\\:\\ 0\\.038088666041301955\ \(0\)\
\-\ that\\:\\ 0\\.038051049371088226\ \(0\)\
\-\ aggressive\\:\\ 0\\.03791197802591677\ \(0\)\
\-\ local\\:\\ 0\\.0377392608657863\ \(0\)\
\-\ schwannoma\\:\\ 0\\.037570339996261325\ \(0\)\
\-\ removed\\:\\ 0\\.03724324424185196\ \(0\)\
\-\ generally\\:\\ 0\\.03713723442079739\ \(0\)\
\-\ poor\\:\\ 0\\.03698091194347129\ \(0\)\
\-\ ventricular\\:\\ 0\\.03687843588962898\ \(0\)\
\-\ disease\\:\\ 0\\.03680612681815669\ \(0\)\
\-\ via\\:\\ 0\\.035833105261159535\ \(0\)\
\-\ be\\:\\ 0\\.03556940884773714\ \(0\)\
\-\ lumbar\\:\\ 0\\.035401216915690946\ \(0\)\
\-\ linear\\:\\ 0\\.03531767706954651\ \(0\)\
\-\ best\\:\\ 0\\.035276245216245866\ \(0\)\
\-\ position\\:\\ 0\\.034952593598203595\ \(0\)\
\-\ hyperintense\\:\\ 0\\.03487376634129346\ \(0\)\
\-\ occurs\\:\\ 0\\.03456630173465717\ \(0\)\
\-\ where\\:\\ 0\\.034454101345265865\ \(0\)\
\-\ evaluate\\:\\ 0\\.034091506265966624\ \(0\)\
\-\ narrowing\\:\\ 0\\.033985981630996906\ \(0\)\
\-\ canal\\:\\ 0\\.033745249954645194\ \(0\)\
\-\ use\\:\\ 0\\.033544744926606564\ \(0\)\
\-\ system\\:\\ 0\\.03344642047032683\ \(0\)\
\-\ similar\\:\\ 0\\.03341392321186883\ \(0\)\
\-\ related\\:\\ 0\\.033317247846932095\ \(0\)\
\-\ previous\\:\\ 0\\.03312747054622378\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.033096291638657495\ \(0\)\
\-\ about\\:\\ 0\\.03282123122299775\ \(0\)\
\-\ like\\:\\ 0\\.0325847328654942\ \(0\)\
\-\ management\\:\\ 0\\.03238360314001198\ \(0\)\
\-\ presence\\:\\ 0\\.03150046057686981\ \(0\)\
\-\ cortical\\:\\ 0\\.031475220520771084\ \(0\)\
\-\ peripheral\\:\\ 0\\.031350248821326004\ \(0\)\
\-\ malignant\\:\\ 0\\.03125171426430475\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.031130296412461775\ \(0\)\
\-\ status\\:\\ 0\\.03059522843530145\ \(0\)\
\-\ cerebral\\:\\ 0\\.0303737263560671\ \(0\)\
\-\ new\\:\\ 0\\.030330181819331368\ \(0\)\
\-\ this\\:\\ 0\\.030129391028237886\ \(0\)\
\-\ cause\\:\\ 0\\.029866800446873745\ \(0\)\
\-\ less\\:\\ 0\\.02982602798958179\ \(0\)\
\-\ radiation\\:\\ 0\\.029052955709939158\ \(0\)\
\-\ differential\\:\\ 0\\.028486019310443877\ \(0\)\
\-\ found\\:\\ 0\\.02836738601514508\ \(0\)\
\-\ mr\\:\\ 0\\.02836738601514508\ \(0\)\
\-\ show\\:\\ 0\\.027831531295378138\ \(0\)\
\-\ clinical\\:\\ 0\\.02778462012120218\ \(0\)\
\-\ t1\\:\\ 0\\.027315933539388007\ \(0\)\
\-\ treated\\:\\ 0\\.02730128036016463\ \(0\)\
\-\ primary\\:\\ 0\\.026957733104272925\ \(0\)\
\-\ for\\:\\ 0\\.026575985427606003\ \(0\)\
\-\ likely\\:\\ 0\\.026198538635978232\ \(0\)\
\-\ lymphoma\\:\\ 0\\.02611027001812611\ \(0\)\
\-\ she\\:\\ 0\\.026097742566005198\ \(0\)\
\-\ with\\:\\ 0\\.025754084288478904\ \(0\)\
\-\ if\\:\\ 0\\.02547294449262579\ \(0\)\
\-\ t2\\:\\ 0\\.02522316921102972\ \(0\)\
\-\ due\\:\\ 0\\.02520085978992344\ \(0\)\
\-\ therapy\\:\\ 0\\.025189729317051855\ \(0\)\
\-\ cell\\:\\ 0\\.025079302271180427\ \(0\)\
\-\ surgery\\:\\ 0\\.023570992437833997\ \(0\)\
\-\ imaging\\:\\ 0\\.023040140854722516\ \(0\)\
\-\ most\\:\\ 0\\.02281639358713747\ \(0\)\
\-\ have\\:\\ 0\\.02190118545833803\ \(0\)\
\-\ images\\:\\ 0\\.020279567596602155\ \(0\)\
\-\ was\\:\\ 0\\.015279162918973072\ \(0\)\
